Jump to content
  • Sign Up
Sign in to follow this  
rss

PubMed RSS Feed - -Recommendations for rosacea diagnosis, classification and management: Update from the global ROSacea COnsensus (ROSCO) 2019 panel.

Recommended Posts

Related Articles

Recommendations for rosacea diagnosis, classification and management: Update from the global ROSacea COnsensus (ROSCO) 2019 panel.

Br J Dermatol. 2019 Aug 07;:

Authors: Schaller M, Almeida LMC, Bewley A, Cribier B, Del Rosso J, Dlova NC, Gallo RL, Granstein RD, Kautz G, Mannis MJ, Micali G, Oon HH, Rajagopalan M, Steinhoff M, Tanghetti E, Thiboutot D, Troielli P, Webster G, Zierhut M, van Zuuren EJ, Tan J

Abstract
BACKGROUND: A transition from subtyping to a phenotyping approach in rosacea is underway, allowing individual patient management according to presenting features instead of categorisation by pre-defined subtypes. The ROSCO 2017 recommendations further supported this transition and align with guidance from other working groups.
OBJECTIVES: To update and extend previous global ROSCO recommendations in line with the latest research and continue supporting uptake of the phenotype approach in rosacea through clinical tool development.
METHODS: Nineteen dermatologists and two ophthalmologists used a modified Delphi approach to reach consensus on statements pertaining to critical aspects of rosacea diagnosis, classification and management. Voting was electronic and blinded.
RESULTS: Delphi statements on which the panel achieved consensus of ≥75% voting 'Agree' or 'Strongly agree' are presented. The panel recommends discussing disease burden with patients during consultations, using four questions to assist conversations. The primary treatment objective should be achievement of complete clearance, due to previously established clinical benefits for patients. Cutaneous and ocular features are defined. Treatments have been reassessed in line with recent evidence and the prior treatment algorithm updated. Combination therapy is recommended to benefit patients with multiple features. Ongoing monitoring and dialogue should take place between physician and patients, covering defined factors to maximise outcomes. A prototype clinical tool (Rosacea Tracker) and patient case studies have been developed from consensus statements.
CONCLUSIONS: The current survey updates previous recommendations as a basis for local guideline development and provides clinical tools to facilitate a phenotype approach in practice and improve rosacea patient management. This article is protected by copyright. All rights reserved.

PMID: 31392722 [PubMed - as supplied by publisher]

{url} = URL to article

Share this post


Link to post
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

Sign in to follow this  

  • Featured Product

  • Latest Products

    • Miaderm-L

      $42.00 NOTE: Our shopping cart is disabled. We are using it to display affiliate items which if you click on PURCHASE in the PRODUCT INFORMATION by scrolling below or click on the Amazon banner the RRDi receives a small affiliate fee upon completion of your purchase. Mahalo.

      (0)
    • Miaderm Radiation Relief

      $36.00 NOTE: Our shopping cart is disabled. We are using it to display affiliate items which if you click on PURCHASE in the PRODUCT INFORMATION by scrolling below or click on the Amazon banner the RRDi receives a small affiliate fee upon completion of your purchase. Mahalo.

      (0)
×
×
  • Create New...